Introduction
============

Lung cancer is the most prevalent type of cancer in the world. According to the World Health Organization (WHO), about 1.59 million cases of lung cancer-related deaths were recorded worldwide in 2012; and among those, 597 thousand cases took place in China. As a populated country with lots of risk factors such as smoking and air pollution, medical care departments in China is facing with a growing burden of cancer treatment. Therefore, it is crucial to uncover the mechanism of lung cancer formation and thus develop new biomarkers for the detection and treatment of the disease. DEK is an ubiquitous protein in multicellular organisms as well as in some unicellular organisms ([@b1-ol-0-0-8436]). It was originally discovered as a fusion protein with CAN nucleoprotein in a subtype of acute myeloid leukemia in 1992 ([@b2-ol-0-0-8436]). Recent findings showed that DEK may act as an oncoprotein during tumor formation, because of its active role in regulating cell proliferation, differentiation, migration, apoptosis, senescence, self-renewal and DNA repairing ([@b3-ol-0-0-8436]). Meanwhile, it has been found that DEK is over-expressed in various malignant tumor cells, such as neuroendocrine prostate cancer cells, gastric adenocarcinoma cells, colorectal cancer cells, breast cancer cells, bladder cancer cells, human hepatocellular carcinoma cells and so on, while it remains in a low level or is even undetectable in quiescent and terminally differentiated cells ([@b4-ol-0-0-8436]--[@b16-ol-0-0-8436]). Over-expression of DEK boosts proliferation and transformation of epithelial cells, promotes tumor growth and metastasis of breast cancer cells, while it inhibits normal cell differentiation, suppresses p53 pathway-induced apoptosis and acts as a senescence inhibitor with E6 and E7 oncogene ([@b17-ol-0-0-8436],[@b18-ol-0-0-8436]). DEK depletion, on the other hand, may trigger cell apoptosis or senescence ([@b19-ol-0-0-8436]--[@b23-ol-0-0-8436]), and also sensitize cells to chemotherapy or genotoxic agents ([@b9-ol-0-0-8436],[@b23-ol-0-0-8436]--[@b26-ol-0-0-8436]). These facts demonstrate the potential applications of DEK as a tumor diagnostic biomarker and also as a therapeutic target.

This study focused on the poorly understood function of DEK in lung cancer cells, and discovered the clinical pathological significance of DEK in lung cancer detection and treatment.

Materials and methods
=====================

### Clinical samples and ethics statement

In this study, 81 specimens of surgically resected lung tumors as well as corresponding adjacent precancerous tissue (with 30 cm distance from the tumor\'s edge) and/or normal tissues (with 50 cm distance from the tumor\'s edge) were collected at the Fourth Military Medical University Affiliated Tangdu Hospital and the General Hospital of People\'s Liberation Army from December 2010 to November 2014 after receiving the patients\' informed consent and the approval of hospital authorities. None of the patients received radiotherapy or chemotherapy prior to the pulmonary surgery. After surgical removal, all of the samples were immediately snap-frozen in liquid nitrogen and stored at −80°C for RNA (29 cases) and protein analyses. All cancerous tissues were primary tumors according to the International Union against Cancer guidelines. The Beijing Jiaotong University Institutional Review Board approved the present study.

### Cell cultures, siRNAs and plasmids

A549 cell line was obtained from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco\'s Modified Eagle Medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (FBS) and were passaged every 3 days using 0.25% trypsin (Merck KGaA, Darmstadt, Germany). The siRNA targeting DEK CDS region was synthesized by Invitrogen, and it was transfected into A549 cells using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Sequences of the siRNAs are listed ([Table I](#tI-ol-0-0-8436){ref-type="table"}). The pcDNA3.1-hDEK plasmid was constructed using the pcDNA3.1 (−) plasmid and the DEK CDS sequence with a 6xCAT Histidine Tag at its N-terminal. A corresponding negative control plasmid was constructed with an EGFP CDS sequence replacing the His-DEK, and it acted as a positive control for the transfection.

### RNA extraction and reverse transcription-PCR

Total RNA was extracted from the lung tumor and matched non-tumorous tissues using Trizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). A total of 1.5 µg mRNA aliquot from each sample were reverse transcribed to double-stranded cDNAs using Go Script^™^ Reverse Transcription System (Promega Corporation, Madison, WI, USA) with the final volume of 20 µl. Quantitative reverse transcription-PCR (qRT-PCR) was performed using Super Real PreMix Plus (SYBR Green; Tiangen Biotech Co., Ltd., Beijing, China) and Light Cycler 480 (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer\'s protocol. cDNAs were diluted into quarters and 1 µl of diluted cDNAs were added into the reaction mix with the final volume of 20 µl. Reaction conditions were as followed: 95°C 15 min; followed by 40 cycles of 95°C 10 sec, 60°C 20 sec (signal acquisition). Experiment was performed in triplicates and the fold change of each gene was calculated using the 2^−ΔΔCt^ method. Primers used in this experiment are listed ([Table II](#tII-ol-0-0-8436){ref-type="table"}).

### Immunohistochemistry

Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded tumor tissues, which were sectioned (4 mm) and mounted on polylysine-coated slides. The sections were deparaffinized in xylene and then rehydrated in decreasing concentrations of ethanol (100, 95, 80 and 70%, respectively). Antigen was retrieved by incubating sections with sodium citrate buffer (pH 6.0) for 10 min in the microwave. Slides were incubated with 3% (v/v) H~2~O~2~ for 15 min to inhibit endogenous peroxidase activity. To further reduce non-specific background staining, sections were incubated in 20% (v/v) normal goat serum for 20 min and were then incubated with the DEK-specific primary rabbit antibody (dilution 1:300; ProteinTech Group, Inc., Chicago, IL, USA) at 37°C for 2 h. The Goat anti Rabbit IgG/HRP polymer conjugate (OriGene Technologies, Inc., Rockville, MD, USA) were added to the sections and incubated at 37°C for 15 min according to the manufacturer\'s protocol. Between each aforementioned steps, the sections were washed with phosphate-buffered saline (PBS) for 6 min. Immunostaining was visualized by developing the slides in diaminobenzidin (DAB). The sections were counterstained with hematoxylin for 4 sec, dehydrated and mounted. Each slide was observed under the microscope at magnification, ×400. Semi-quantitative percentage score was given according to the nuclear staining of cells from five views. Percentage scores were assigned as follows: 0--5%: negative (−), 6--25%: weak positive (+), 26--50%: positive (++), 51--100%: strong positive (+++).

### Western blotting analysis

Cells were trypsinized after transfection for 48 h using 0.25% trypsin (Merck KGaA), then lysed using 1X SDS-PAGE loading buffer \[0.045 mol/l Tris-HCl (pH 6.8); 10% glycerin, 1% SDS; 0.004% bromophenol blue; 0.5 mol/l DTT; with a final concentration of 200 µl loading buffer every 1×10^6^ cells\]. 30 µl of each sample was loaded and separated in a 12% SDS-polyacrylamide gel by electrophoresis. Proteins were transferred onto nitrocellulose filter membrane (NC membrane; Pall Life Sciences, Port Washington, NY, USA) and incubated in the following reagents: 5% non-fat milk (4°C, over-night); primary antibodies (DEK rabbit polyclonal antibody: 1:1,000, ProteinTech Group, Inc.; β-actin mouse monoclonal antibody: 1:1,000, OriGene Technologies, Inc.; His mouse monoclonal antibody: 1:500, OriGene Technologies, Inc.); secondary antibodies (Peroxidase-Conjugated AffiniPure Goat anti-mouse IgG: 1:2,000, OriGene Technologies, Inc.; or Peroxidase-Conjugated AffiniPure Goat anti-rabbit IgG: 1:2,000, OriGene Technologies, Inc.; 37°C, 1 h). After each aforementioned incubation step, the membrane was washed in TBST buffer for 3 times, 5 min each time. So were the reagent and antibodies diluted in TBST buffer. After the final washing step, bound proteins were visualized using ECL (Thermo Fisher Scientific, Inc.) and X-ray film (Fujifilm, Shanghai, China). The relative expression level of each gene was analyzed based on β-actin as the loading control.

### MTT assay

A549 cells were planted on 96-well plate before transfection, with 100 µl of medium, 1,000 cells per well. 10 µl MTT reagent was added to wells 24, 48, 72 and 96 h after transfection, and the plate was incubated in 37°C for 4 h. After discarding the media, 100 µl of DMSO was added to dissolve the MTT formazan in each well. The plate was incubated in 37°C for another 4 h and the optical density was read using a wavelength of 570 nm. Each test was performed in triplicates.

### Colony formation assay

Cells were replanted in 6-well cell culture dishes 48 h after transfection with 1,000 cells per well. Medium was renewed every two days. 7 days after transfection, colonies were stained by 0.1% crystal violet (Beyotime Institute of Biotechnology, Haimen, China), and visible colonies were counted. Each test was performed in triplicates.

### Matrigel cell invasion assay

48 h after transfection, 10,000 cells were replanted onto the upper membrane of transwell chamber (EMD Millipore, Billerica, MA, USA) covered with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer\'s protocol. The upper chamber contained 200 µl of DMEM, and the lower chamber contained 600 µl of DMEM with 10% FBS as chemoattractant. 24 h after incubation, the chamber was washed with PBS and cells on the upper membrane were gently removed. Then the membrane was stained with crystal violet (Beyotime Institute of Biotechnology, Haimen, China). Number of migrated cells were counted under the microscope with magnification, ×100, 5 randomly selected areas on each membrane were counted.

### Statistical analysis

All data were analyzed using SPSS version 20. Immunohistochemistry results were analyzed using the chi-squared tests, and all other results were analyzed using the unpaired, two-tailed Student\'s t-tests. All statistical data were presented as means ± standard deviation. A test with a P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Over-expression of DEK mRNA detected in lung cancerous tissues

Real-time quantitative RT-PCR (qRT-PCR) was performed in 29 cases of lung cancerous tissues paired with non-cancerous counterparts. DEK-over expression means that in tumor samples the DEK is more expressed than in the adjacent normal tissue samples. As shown in [Table III](#tIII-ol-0-0-8436){ref-type="table"}, DEK mRNA was over-expressed in 15 out of 29 (51.7%) cases of lung cancerous tissues paired with normal tissues. Among those, 14 cases (48.3%) showed over two-fold up-regulation of DEK mRNA level, 9 cases (31.0%) showed over five-fold up-regulation of DEK mRNA level. In adenocarcinoma tissues, 7 out of 8 cases (87.5%) showed over-expression of DEK mRNA, which was significantly higher than those of other histopathological types. However, no correlation between the over-expression of DEK mRNA and patient\'s age, gender, pleural invasion status as well as TMN stage was found ([Table IV](#tIV-ol-0-0-8436){ref-type="table"}).

### Over-expression of DEK protein detected in lung cancerous tissues

The expression level of DEK protein in lung cancerous tissues and non-cancerous counterparts were detected by IHC ([Fig. 1](#f1-ol-0-0-8436){ref-type="fig"}). Among 81 cases of lung cancerous tissues, 66 cases (81.5%) showed positive staining of DEK protein, while 32 cases (39.5%) showed strong positive staining of DEK protein, which was significantly higher than those in normal tissues ([Table V](#tV-ol-0-0-8436){ref-type="table"}). However, there was no significant correlation between strong positive staining of DEK protein and clinicopathological characteristics of patients ([Table VI](#tVI-ol-0-0-8436){ref-type="table"}).

### DEK depletion and over-expression in A549 lung cancer cells

To further investigate the function of DEK in lung cancer cells, siRNA as well as plasmid encoding His-tagged DEK CDS were employed respectively to down-regulate and up-regulate the expression level of DEK in A549 lung cancer cell line. The expression level of DEK mRNA and protein were analyzed by qRT-PCR and Western Blotting (WB). Results showed the expression level of DEK mRNA and protein were down-regulated by siRNA transfection; while the transfection of plasmid encoding His-tagged DEK caused DEK over-expression in A549 cells ([Fig. 2](#f2-ol-0-0-8436){ref-type="fig"}).

### DEK positively regulates proliferation in A549 cells

To detect whether DEK could regulate cell proliferation in lung cancer cell lines, MTT assay was performed in DEK depleted and over-expressed A549 cells. Results showed that cell proliferation was significantly restricted after day 4 in DEK depleted cells, while being significantly promoted after day 3 and day 4 in DEK over-expressed cells ([Fig. 3A and B](#f3-ol-0-0-8436){ref-type="fig"}). A supplementary experiment of colony formation assay was performed and the results were in accordance with the former one. A significant decrease of colony numbers in DEK depleted cells and a significant increase of colony numbers in DEK over-expressed cells were detected ([Fig. 3C-F](#f3-ol-0-0-8436){ref-type="fig"}). Both experiments manifested the positive correlation between DEK expressional level and cell proliferation, showing DEK may act as a pro-proliferation factor in A549 cells. As a chromatin associated architectural protein, DEK may play an important role in change of chromatin structure and thereby the expression of genes related to cell proliferation.

### DEK positively regulates invasion of A549 cells

Matrigel invasion assay was performed to detect alterations DEK made to cell invasion. Decrease of invaded cell numbers was shown in DEK depleted A549 cells, while DEK over-expressed cells resulted in an increase of invaded cell numbers ([Fig. 4](#f4-ol-0-0-8436){ref-type="fig"}). According to the results, the invasion of A549 cells was positively correlated with DEK expression.

Discussion
==========

DEK is over-expressed in various type of malignant carcinomas, such as acute myeloid leukemia, retinoblastoma, brain malignant glioma, hepatocellular carcinoma, breast cancer, uterine cervical cancer, bladder cancer, colon cancer, colorectal cancer, gastric adenocarcinoma, oral squamous cell carcinoma, neuroendocrine prostate cancer ([@b5-ol-0-0-8436]--[@b8-ol-0-0-8436],[@b10-ol-0-0-8436]--[@b17-ol-0-0-8436],[@b27-ol-0-0-8436]). It was first discovered that DEK was over-expressed in high-grade neuroendocrine carcinoma of the lung by Shibata *et al* ([@b9-ol-0-0-8436]), yet it was only limited on the type of neuroendocrine carcinoma. Here we examined the expression level of DEK in various subtypes of lung cancer, and discovered that DEK mRNA is over-expressed in 51.7% of lung cancerous tissues. Especially, in adenocarcinoma tissues of the lung, DEK showed a significantly high over-expression rate of 87.5%. The IHC experiment showed similar results, 39.5% of lung cancerous tissues showed strong positive expression of DEK protein, while the number was only 20.5% in normal tissues. These findings gave valuable hints to the biomarker development of DEK, showing that DEK might have the potential to be applied as a diagnostic biomarker for lung cancers, especially for adenocarcinoma of the lung. However, neither of these studies demonstrated the relationship between DEK expression and patient\'s age, gender, or TMN stage, differentiation status of the carcinoma.

We have analyzed the expression of DEK in mRNA and protein level in lung cancer samples, not only the NSCLC samples reported in the study by Liu *et al* ([@b28-ol-0-0-8436]), which explored the role of DEK expression for the prognostic evaluation of non-small cell lung carcinoma (NSCLC). Besides, based on the previous findings, the downstream effects of aberrant DEK expressional level were analyzed using the A549 lung cancer cell line. Through silence and overexpression of DEK in A549 cells, we found that DEK could influence the proliferation and invasion of A549 tumor cells. In our study, it was discovered that the over-expression of DEK promotes cell proliferation and invasion, which was in accordance with former studies in other types of cancers ([@b3-ol-0-0-8436],[@b8-ol-0-0-8436],[@b17-ol-0-0-8436],[@b19-ol-0-0-8436]). The findings support the carcinogenic role of DEK in lung cancer formation, and it could be the reason for the aberrant expressional level of DEK in lung cancerous tissues we detected earlier. On the other hand, depletion of DEK in A549 cells gave us the exact opposite story. Our study showed that DEK depletion could repress proliferation and invasion of lung tumor cells. Therefore, DEK could act as a target for lung tumor therapy applied in clinical studies. In our study, the depletion of the gene expression was accomplished by siRNA transfection, which made the therapy easier to be applied clinically.

To sum up, the present study discovered that DEK was over-expressed in lung cancerous tissues. The aberrant expression of DEK may promote cell survival and tumorigenesis. The more detailed discussion of DEK\'s mechanism in lung cancer formation should be done in the future studies, and clinical studies using larger groups of samples should be performed to discover the further application value of DEK as a novel biomarker.
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![Detection of DEK protein in lung cancerous tissues. (A) Strong positive staining (+++) of DEK protein in lung cancerous tissues. (B) Positive staining (++), (C) weak positive staining (+) and (D) negative staining (−) of DEK protein in lung cancerous tissues. (E) Precancerous and (F) normal tissues corresponding to the cancerous tissue in part A. Each showing negative staining of the DEK protein. Each slide was observed under the microscope at magnification, ×400. Semi-quantitative percentage score was given according to the nuclear staining of cells from five views. Arrows in the pictures indicate a positive stain. Scale bars, 20 µm.](ol-15-06-8573-g00){#f1-ol-0-0-8436}

![Depletion and over-expression of DEK in A549 cells. The expressional level of DEK mRNA and protein was analyzed 48 h post transfection. A549 cells transfected with DEK-targeting siRNA showed significant decrease in DEK (A) mRNA and (B) protein expressional level compared with the control group. A549 cells transfected with DEK over-expressing plasmid showed a significant increase in DEK (C) mRNA and (D) protein expressional level compared with the control group. Anti-His tag antibodies were used to verify whether the over-expressing DEK was the product of the plasmid transfected. \*\*\*P\<0.001 vs. the control.](ol-15-06-8573-g01){#f2-ol-0-0-8436}

![DEK positively regulates A549 cell proliferation. An MTT assay revealed (A) a reduction of 570 nm absorbance in DEK depleted cells after day 4 (B) and an increased absorbance in DEK over-expressed cells after day 3 and day 4. The colony formation assay revealed that (C) fewer colonies were formed after DEK was depleted (D) while more colonies were formed after the over-expression of DEK. Both assays were performed in triplicate. The colonies were stained by crystal violet in the (E) siDEK and (F) pDEK groups of treated cells. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. the control. si, short interfering; p, plasmid.](ol-15-06-8573-g02){#f3-ol-0-0-8436}

![DEK positively regulates the invasion of A549 lung cancer cell. Cell invasion was (A) significantly inhibited in DEK-depleted A549 cells, while (B) significantly promoted in DEK over-expressed cells. The assay was performed in triplicates. Cells migrated to the lower surface of the chamber were stained by crystal violet in the (C) siDEK and (D) pDEK groups of treated cells. Scale bars, 100 µm. \*\*P\<0.01 vs. the control. si, short interfering; p, plasmid.](ol-15-06-8573-g03){#f4-ol-0-0-8436}

###### 

List of siRNA sequences.

  Name        Sense-strand sequence (5′ to 3′)   Antisense-stand sequence (5′ to 3′)
  ----------- ---------------------------------- -------------------------------------
  siRNA-DEK   GGAUAGUUCAGAUGAUGAACCdTdT          GGUUCAUCAUCUGAACUAUCC dTdT
  siRNA-NC    UUCUCCGAACGUGUCACGU dTdT           ACGUGACACGUUCGGAGAAdTdT

siRNA, short interfering RNA.

###### 

Primers used in the experiment.

  Name of primer   Sequence (5′ to 3′)             Product size (bp)
  ---------------- ------------------------------- -------------------
  DEK-Fw           TGTTAAGAAAGCAGATAGCAGCACC         96
  DEK-Rv           ATTAAAGGTTCATCATCTGAACTATCCTC   
  B2M-Fw           GGCTATCCAGCGTACTCC              247
  B2M-Rv           ACGGCAGGCATACTCATC              
  GAPDH-Fw         TGACATCAAGAAGGTGGTGAAGCAGG      123
  GAPDH-Rv         GCGTCAAAGGTGGAGGAGTGGGT         
  p53-Fw           GCGAGCACTGCCCAACAACA              83
  p53-Rv           GGATCTGAAGGGTGAAATATTCT         
  p65-Fw           ATGTGGAGATCATTGAGCAGC           152
  p65-Rv           CCTGGTCCTGTGTAGCCATT            
  ATM-Fw           TTGATCTTGTGCCTTGGCTAC           142
  ATM-Rv           TATGGTGTACGTTCCCCATGT           
  DEK-BSP-Fw       GGGATTGTTTATTATTTTTTTTAGGAAG    388
  DEK-BSP-Rv       CGACTCCCCAAAATCAACAAAAT         

###### 

Association between DEK mRNA expression and tissue position.

  Groups compared                 Cases   DEK over-expressed (%)   DEK not over-expressed (%)
  ------------------------------- ------- ------------------------ ----------------------------
  Cancerous/normal tissue         29      15 (51.7)                14 (48.3)
  Cancerous/precancerous tissue   30      11 (36.7)                19 (63.3)
  Precancerous/normal tissue      24      10 (41.7)                14 (58.3)

###### 

Association between DEK mRNA expression and clinicopathological characteristics.

  Clinicopathological characteristic   Cases   DEK over-expressed (%)   DEK not over-expressed (%)   χ^2^    P-value
  ------------------------------------ ------- ------------------------ ---------------------------- ------- ----------------------------------------------------
  Total                                29      15 (51.7)                14 (48.3)                            
  Age                                                                                                0.181   0.671
    ≤60                                12      7 (58.3)                 5 (41.7)                             
    \>60                               14      7 (50.0)                 7 (50.0)                             
    Unknown                            3       1 (33.3)                 2 (66.7)                             
  Gender                                                                                             0.379   0.678
    Male                               19      11 (57.9)                8 (42.1)                             
    Female                             7       3 (42.9)                 4 (57.1)                             
    Unknown                            3       1 (33.3)                 2 (66.7)                             
  Pleural invasion                                                                                   0.422   0.516
    Positive                           10      6 (60.0)                 4 (40.0)                             
    Negative                           17      8 (47.1)                 9 (52.9)                             
    Unknown                            2       1 (50.0)                 1 (50.0)                             
  Histopathological type                                                                             8.471   0.132
    NSCLC                              22      12 (54.5)                10 (45.5)                    0.049   \>0.999
    Adenocarcinoma                     8       7 (87.5)                 1 (12.5)                     4.698   0.043^[a](#tfn2-ol-0-0-8436){ref-type="table-fn"}^
    Squamous carcinoma                 9       3 (33.3)                 6 (66.7)                             
    Adenosquamous carcinoma            2       1 (50.0)                 1 (50.0)                             
    Sarcomatoid carcinoma              2       0 (0.0)                  2 (100.0)                            
    Large cell carcinoma               1       1 (100.0)                0 (0.0)                              
    Small cell carcinoma               5       3 (60.0)                 2 (40.0)                             
    Unknown                            2       0 (0.0)                  2 (100.0)                            
  TMN                                                                                                2.912   0.573
    Benign tumor                       1       0 (0.0)                  1 (100.0)                            
    I                                  10      6 (60.0)                 4 (40.0)                             
    II                                 7       4 (57.1)                 3 (42.9)                             
    III                                10      4 (40.0)                 6 (60.0)                             
    IV                                 1       1 (100.0)                0 (0.0)                              
  Differentiation                                                                                            
    Well to moderately-well            4       4 (100.0)                0 (0.0)                              
    Moderate to poor                   3       3 (100.0)                0 (0.0)                              
    Unknown                            1       0 (0.0)                  1 (100.0)                            

P\<0.05 vs. non-adenocarcinoma samples. NSCLC, non-small cell lung cancer; TNM, tumor, node, metastasis.

###### 

Association between DEK protein expression and tissue position according to immunohistochemistry results.

  Sample   Cases   −    \+   ++   +++   Positive rate (%)   Strong positive rate (%)
  -------- ------- ---- ---- ---- ----- ------------------- ---------------------------------------------------
  C        81      15   34   21   11    81.5                39.5^[a](#tfn3-ol-0-0-8436){ref-type="table-fn"}^
  P        81      13   45   21     2   84.0                28.4
  N        73      23   35   13     2   68.5                20.5

P\<0.05 vs. normal tissues samples. -, 0--5%; +, 6--25%; ++, 26--50%; +++, 51--100%. C, Cancerous tissue sample; P, adjacent precancerous tissue sample; N, normal tissue sample.

###### 

Association between DEK protein expression and clinicopathological characteristics.

  Clinicopathological characteristic   Cases   Strong positive staining of DEK in cancerous tissues, +++ or ++ (%)   Weak or negative staining of DEK in cancerous tissues, + or - (%)   χ^2^    P-value
  ------------------------------------ ------- --------------------------------------------------------------------- ------------------------------------------------------------------- ------- ---------
  Total                                81      32 (39.5)                                                             49 (60.5)                                                                   
  Age                                                                                                                                                                                    2.339   0.126
    ≤60                                40      14 (35.0)                                                             26 (65.0)                                                                   
    \>60                               30      16 (53.3)                                                             14 (46.7)                                                                   
    Unknown                            11      2 (18.2)                                                              9 (81.8)                                                                    
  Gender                                                                                                                                                                                 2.500   0.114
    Male                               49      24 (49.0)                                                             25 (51.0)                                                                   
    Female                             21      6 (28.6)                                                              15 (71.4)                                                                   
    Unknown                            11      2 (18.2)                                                              9 (81.8)                                                                    
  Pleural invasion                                                                                                                                                                       0.002   0.968
    Positive                           16      10 (62.5)                                                             6 (37.5)                                                                    
    Negative                           19      12 (63.2)                                                             7 (36.8)                                                                    
    Unknown                            46      10 (21.7)                                                             36 (78.3)                                                                   
  Histopathological type                                                                                                                                                                 5.344   0.375
    NSCLC                              61      25 (41.0)                                                             36 (59.0)                                                           0.039   \>0.999
    Adenocarcinoma                     24      7 (29.2)                                                              17 (70.8)                                                                   
    Squamous carcinoma                 24      11 (45.8)                                                             13 (54.2)                                                                   
    Adenosquamous carcinoma            4       2 (50.0)                                                              2 (50.0)                                                                    
    Sarcomatoid carcinoma              5       4 (80.0)                                                              1 (20.0)                                                                    
    Large cell carcinoma               4       1 (25.0)                                                              3 (75.0)                                                                    
    Small cell carcinoma               9       4 (44.4)                                                              5 (55.6)                                                                    
    Unknown                            11      3 (27.3)                                                              8 (72.7)                                                                    
  TMN                                                                                                                                                                                    2.167   0.705
    Benign tumor                       1       1 (100.0)                                                             0 (0.0)                                                                     
    I                                  19      8 (42.1)                                                              11 (57.9)                                                                   
    II                                 12      6 (50.0)                                                              6 (50.0)                                                                    
    III                                25      14 (56.0)                                                             11 (44.0)                                                                   
    IV                                 3       1 (33.3)                                                              2 (66.7)                                                                    
    Unknown                            21      2 (9.5)                                                               19 (90.5)                                                                   
  Differentiation                                                                                                                                                                        0.198   0.673
    Well to moderately-well            9       3 (33.3)                                                              6 (66.7)                                                                    
    Moderate to poor                   16      4 (25.0)                                                              12 (75.0)                                                                   
    Unknown                            56      25 (44.6)                                                             31 (55.4)                                                                   

-, 0--5%; +, 6--25%; ++, 26--50%; +++, 51--100%. NSCLC, non-small cell lung cancer; TNM, tumor, node, metastasis.

[^1]: Contributed equally
